Results 201 to 210 of about 1,768,893 (247)

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine. [PDF]

Pathogens, 2020
Hilimire TA, Nogales A, Chiem K, Ortego J, Martinez-Sobrido L.   +4 more
europepmc   +1 more source

The Potential of Live, Attenuated Influenza Vaccine for the Prevention of Influenza in Children

Clinical Infectious Diseases, 2018
openaire   +2 more sources

Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents. [PDF]

Front Immunol
Sampson OL, Jay C, Adland E, Csala A, Lim N, Ebbrecht SM, Gilligan LC, Taylor AE, George SS, Longet S, Jones LC, Barnes E, Frater J, Klenerman P, Dunachie S, Carrol M, Hawley J, Arlt W, Groll A, Goulder P.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Influenza Vaccination with a Live Attenuated Vaccine

AJN, American Journal of Nursing, 2009
Influenza is a highly contagious, acute respiratory illness with a long history of outbreaks dating back several centuries. Although immunization is an effective means of protection against influenza, vaccination rates have been suboptimal, especially among certain high-risk groups, including children and health care personnel.
Michele, Michael, Elizabeth, Helm, Brigit, Van Graafeiland, Frank, Malinoski, Jay, Bauman   +4 more
openaire   +2 more sources

Generation of a live attenuated influenza A vaccine by proteolysis targeting

Nature Biotechnology, 2022
The usefulness of live attenuated virus vaccines has been limited by suboptimal immunogenicity, safety concerns or cumbersome manufacturing processes and techniques. Here we describe the generation of a live attenuated influenza A virus vaccine using proteolysis-targeting chimeric (PROTAC) technology to degrade viral proteins via the endogenous ...
Chengxin Zhang, Longlong Si, Roberto Plebani   +2 more
exaly   +3 more sources

Live Attenuated Influenza Vaccine in Children

Seminars in Pediatric Infectious Diseases, 2006
Live attenuated influenza vaccine (LAIV) offers a novel approach to influenza vaccination and is approved for healthy individuals 5 to 49 years of age. In placebo-controlled studies in children, LAIV was 73 to 93 percent efficacious, and protection lasted more than 12 months.
Christopher S, Ambrose, Robert E, Walker, Edward M, Connor   +2 more
openaire   +2 more sources

Live Attenuated Influenza Vaccine

2014
Cold-adapted Ann Arbor based live attenuated influenza vaccine (LAIV) has been available in the USA since 2003. The vaccine is efficacious against influenza infection. Features of LAIV include: easy administration suitable for mass immunization, cross-reactivity to drifted strains for broader coverage, and establishment of herd immunity for control of ...
Hong, Jin, Kanta, Subbarao
openaire   +2 more sources

Live attenuated influenza vaccine

2008
The development of the live, attenuated influenza vaccine (LAIV), based on the cold-adapted (ca), attenuated ca A/Ann Arbor/6/60 and ca B/Ann Arbor/1/66 backbones, has spanned several decades. The vaccine contains three vaccine strains, two attenuated influenza A strains and one attenuated influenza B strain; these vaccine strains are genetic ...
Harry Greenberg, George Kemble
openaire   +1 more source

Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines

New England Journal of Medicine, 2009
The efficacy of influenza vaccines may vary from year to year, depending on a variety of factors, and may differ for inactivated and live attenuated vaccines.We carried out a randomized, double-blind, placebo-controlled trial of licensed inactivated and live attenuated influenza vaccines in healthy adults during the 2007-2008 influenza season and ...
Joshua G Petrie, John C. Victor, Arnold S. Monto   +2 more
exaly   +3 more sources

Live Attenuated Vaccines for Pandemic Influenza

2009
In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter.
Grace L, Chen, Kanta, Subbarao
openaire   +2 more sources